Cannabics Pharmaceuticals Inc., a global leader in the development of cancer related cannabinoid-based medicine, announced today that Dr. Yonina Tova (MD), internationally recognized Radiation Oncologist has joined the company’s Board of Advisors.
Dr. Tova obtained her Medical Degree from the College of Medicine, University of Illinoi, Chicago, in 1986. Dr. Tova specializes in treating cancer with radiation, using radiation therapy to treat a wide variety of cancers. Dr. Tova is certified by the American Board of Radiology (ABR), and currently serves as Director of the Radiotherapy Institute at Ziv Hospital in Israel.
Company Director and Head of Advisory Board, Dr. Gil Feiler, commented: “It is with great pleasure that I welcome Dr. Yonina Tova to our Advisory Board. The Company is focused on the advancement of our flagship drug candidate RCC-33 for the treatment of colorectal cancer. And as the company continues to prepare its approach towards Phase I/II (a) studies, we are constantly expanding our team of clinical experts to help us maximize our potential positive impact on current standard of care and on patient outcome. I am certain that Dr. Tova, who is highly renowned and experienced in the field of Oncological Radiation, will have a significant contribution to this process”.
Read more:
Recent expansion of Company’s IP Portfolio with filing of 2 new Provisional Patents; Recent expansion of Cannabics Pharmaceuticals’ Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.); Recent expansion of Cannabics Pharmaceuticals’ Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com.